Citation: | WANG Kaizhen, YANG Wanwan, XU Shengyao, GUO Qinglong, ZHAO Li. Effects and mechanisms of AKR1C3 inducing doxorubicin resistance in breast cancer[J]. Journal of China Pharmaceutical University, 2021, 52(3): 352-360. DOI: 10.11665/j.issn.1000-5048.20210313 |
[1] |
. CA Cancer J Clin,2019,69(1):7-34.
|
[2] |
Xu ML,Wang C,Wang N,et al. MALAT1 upregulates SMYD3 by competition with miR-124 and promotes proliferation and migration of breast cancer cells[J]. J China Pharm Univ(中国药科大学学报),2019,50(3):344-351.
|
[3] |
Greenlee H,Dupont-Reyes MJ,Balneaves LG,et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment[J]. CA Cancer J Clin,2017,67(3):194-232.
|
[4] |
Howard GR,Johnson KE,Rodriguez Ayala A,et al. A multi-state model of chemoresistance to characterize phenotypic dynamics in breast cancer[J]. Sci Rep,2018,8(1):12058.
|
[5] |
Bandyopadhyay A,Wang L,Agyin J,et al. Doxorubicin in combination with a small TGFbeta inhibitor:a potential novel therapy for metastatic breast cancer in mouse models[J]. PLoS One,2010,5(4):
|
[6] |
Turton NJ,Judah DJ,Riley J,et al. Gene expression and amplification in breast carcinoma cells with intrinsic and acquired doxorubicin resistance[J]. Oncogene,2001,20(11):1300-1306.
|
[7] |
Penning TM,Burczynski ME,Jez JM,et al. Human 3alpha-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily:functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones[J]. Biochem J,2000,351(
|
[8] |
Penning TM. AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase):roles in malignancy and endocrine disorders[J]. Mol Cell Endocrinol,2019,489:82-91.
|
[9] |
Liu Y,He SY,Chen Y,et al. Overview of AKR1C3:inhibitor achievements and disease insights[J]. J Med Chem,2020,63(20):11305-11329.
|
[10] |
Boichuk S,Galembikova A,Sitenkov A,et al. Establishment and characterization of a triple negative basal-like breast cancer cell line with multi-drug resistance[J]. Oncol Lett,2017,14(4):5039-5045.
|
[11] |
Yamashita N,Kanno Y,Saito N,et al. Aryl hydrocarbon receptor counteracts pharmacological efficacy of doxorubicin via enhanced AKR1C3 expression in triple negative breast cancer cells[J]. Biochem Biophys Res Commun,2019,516(3):693-698.
|
[12] |
Ruiz de Galarreta M,Bresnahan E,Molina-Sánchez P,et al. β-catenin activation promotes immune escape and resistance to anti-PD-1 therapy in hepatocellular carcinoma[J]. Cancer Discov,2019,9(8):1124-1141.
|
[13] |
Tenbaum SP,Ordó?ez-Morán P,Puig I,et al. β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer[J]. Nat Med,2012,18(6):892-901.
|
[14] |
Huang SM,Mishina YM,Liu SM,et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling[J]. Nature,2009,461(7264):614-620.
|
[15] |
Wu C,Yu S,Tan Q,et al. Role of AhR in regulating cancer stem cell-like characteristics in choriocarcinoma[J]. Cell Cycle,2018,17(18):2309-2320.
|